Congo Ebola Toll Hits 600 As Bundibugyo Strain Outpaces Response

The Ebola outbreak tearing through the eastern Democratic Republic of Congo has now killed 600 people, a grim figure released by the World Health Organisation on Thursday that lays bare how quickly the virus is spreading despite an intensifying containment effort. What alarms health officials most is the pace: the death toll crossed 500 only three days earlier, meaning more than 100 lives were lost in barely 72 hours.

Updated figures compiled by the WHO from Congolese health authorities show 1,759 confirmed cases since the outbreak was declared in mid-May, with 600 of those patients now dead. That puts the case fatality rate at roughly 34 per cent, a sobering ratio that reflects both the severity of the disease and the strain on a health system already stretched thin by years of conflict. Health authorities reported that 285 patients have recovered, while 304 suspected cases remain under investigation.

The epidemic has not stayed within Congo’s borders. Neighbouring Uganda has recorded 20 confirmed cases and two deaths, though 17 of those patients have since recovered, a sign that early detection and isolation can blunt the virus where the systems exist to apply them.

At the centre of the crisis sits Ituri Province, the mineral-rich but conflict-scarred region in the northeast where the first deaths surfaced. Officially declared on May 15, this is Congo’s 17th Ebola outbreak since the virus was first identified in the country in 1976, and it has since fanned out across dozens of health zones in three provinces, namely Ituri, North Kivu and South Kivu. Congolese authorities said late on Wednesday that 750 patients are currently in isolation or hospital care, with bed occupancy running at about 94 per cent, a figure that speaks to treatment centres pushed close to their limits.

What makes this outbreak particularly difficult is the pathogen itself. It is driven by the rare Bundibugyo species of Ebola, first identified in Uganda in 2007, for which there is neither an approved vaccine nor a licensed treatment. That absence sets the current emergency apart from the devastating 2018 to 2020 epidemic in eastern Congo, which was caused by the Zaire strain and killed nearly 2,300 people. For that strain, tools such as the Ervebo vaccine and monoclonal antibody therapies were available. Against Bundibugyo, clinicians have been left to rely largely on supportive care.

In a bid to close that gap, authorities launched a clinical trial on July 2 to test two potential therapies. The study is evaluating the monoclonal antibody MBP134 and the antiviral drug remdesivir, administered both individually and in combination, in the hope of establishing whether either can improve survival.

The response continues to run into formidable obstacles. Officials have cited community resistance to post-mortem sampling, gaps in contact tracing, limited medical supplies, insecurity and restricted access in areas held by armed groups. Broader context underscores the danger. Ebola, transmitted through direct contact with the bodily fluids of infected persons or contaminated materials, has killed more than 15,000 people across Africa over the past half century.

For now, Congolese health teams and their international partners face a race against a virus moving faster than the tools available to stop it.